Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Short Interest Up 161.2% in June

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 222,527 shares, an increase of 161.2% from the May 31st total of 85,189 shares. Currently, 24.2% of the company’s stock are sold short. Based on an average daily trading volume, of 12,012,243 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cuprina Holdings (Cayman) in a research note on Friday, April 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cuprina Holdings (Cayman) presently has a consensus rating of “Sell”.

Cuprina Holdings (Cayman) Stock Up 67.0%

Shares of NASDAQ CUPR traded up $2.99 during trading on Tuesday, reaching $7.45. 22,119,942 shares of the stock traded hands, compared to its average volume of 1,645,189. Cuprina Holdings has a 52-week low of $1.76 and a 52-week high of $76.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.35 and a quick ratio of 2.35. The firm has a 50-day moving average of $2.99.

Cuprina Holdings (Cayman) (NASDAQ:CUPR) last announced its quarterly earnings data on Monday, April 27th. The company reported ($0.40) earnings per share for the quarter. The company had revenue of $0.01 million during the quarter.

About Cuprina Holdings (Cayman)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.